1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Bonesupport Holding AB (publ)

Bonesupport Holding AB (publ)

BOEUF
Bonesupport Holding AB (publ)US flagOther OTC
20.49
USD
- -
- -
1.34BMarket Cap
Bonesupport Holding AB (publ)
BOEUF
(Other OTC)

Recent

price

20.49

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.89
1.34
2.26
3.25
1.9
3
3.06
3.33
5.1
9.1
13.69
17.84
16.14
Revenue per Share
-1.1
-1.29
-2.38
-3.24
-3.46
-3.1
-1.72
-1.34
-1.06
3.77
2.04
2.16
2.25
Basic EPS, GAAP
-1.02
-1.44
-1.8
-2.82
-3.42
-3.24
-1.74
-1.36
-0.78
-0.37
0.91
3.28
3.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-10.63
-11.76
-13.73
-18.53
-17.84
-20.64
-19.69
-20.37
-20.22
-15.7
-12.88
-10.43
-11.63
Book Value per Share
-1.05
0.33
0.65
11.19
5.36
2.25
6.6
4.02
4.04
8.21
10.86
12.94
11.88
Tangible Book Value per Share
46
46
46
40
51
52
59
64
64
65
66
66
66
Basic Weighted Avg Shares
41
62
105
129
97
155
181
213
329
591
899
1,175
1,062
Sales/Revenue/Turnover
-105.15
-87.96
-85.84
-75.4
-181.65
-101.45
-53.19
-39.13
-20.56
3.83
16.44
23.63
17.85
Operating Margin (%)
1
1
1
1
2
8
8
8
9
10
11
12
7
Depreciation Expense
-51
-60
-110
-129
-176
-161
-101
-86
-68
245
134
142
148
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
22.52
28.75
16.35
Effective Tax Rate (%)
-124.67
-96.44
-105.35
-99.67
-182.57
-103.6
-56.07
-40.18
-20.73
41.45
14.88
12.1
13.93
Profit Margin (%)
13
14
114
442
269
107
381
247
249
273
478
632
534
Working Capital
63
- -
85
- -
- -
6
6
16
12
13
8
4
6
LT Debt
-44
20
34
451
279
124
399
266
269
545
727
867
797
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.4
24.17
21.82
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-14.79
-19.2
-17.66
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
7
7
7
LT Borrowings
- -
- -
- -
LT Finance Leases
8
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
25,453
21,589
18,847

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
623
643
694
Cash, Cash Equivalents & STI
227
267
310
Accounts Receivable, Net
196
200
190
Inventories
134
127
132
Total Current Liabilities
144
149
160
Payables & Accruals
- -
- -
- -
ST Debt
7
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
153.34%
24.64%
19.22%
Free Cash Flow
-12.25%
-39.03%
260.66%
Net Income, GAAP
-44.14%
-106.91%
6.28%
Sales/Revenue/Turnover
37.97%
46.94%
30.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
184
220
238
257
899
2025
284
284
313
- -
1,175
2026
324
356
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.33
0.42
0.46
0.82
2.04
2025
0.16
0.81
0.67
- -
2.16
2026
0.81
1.24
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Biotricity, Inc. (BTCY)
Ra Medical Systems, Inc. (RMED)
NewCardio, Inc. (NWCI)
Taiwan Biomaterial Co., Ltd. (6649.TWO)
Carlsmed, Inc. (CARL)
TriSalus Life Sciences, Inc. (TLSI)
Business
Bonesupport Holding AB (publ) is a Sweden-based orthobiologics company specializing in the development and commercialization of injectable bioceramic bone graft substitutes designed to treat bone voids and disorders. The company’s core product portfolio is based on its proprietary CERAMENT technology platform, which includes CERAMENT BVF (Bone Void Filler), CERAMENT G (a gentamicin-eluting bone graft substitute), and CERAMENT V (a vancomycin-eluting product). These products are radiopaque, injectable, osteoconductive, and remodel to host bone while capable of local drug delivery. The company targets conditions including trauma, revision arthroplasty, chronic osteomyelitis, diabetic foot infections, and foot and ankle surgery. Its products are marketed across Europe, North America, India, Malaysia, Oman, and Singapore. Founded in 1999 and headquartered in Lund, Sweden, Bonesupport operates through two geographic segments: North America, and Europe and Rest of the World. Recent strategic developments include strong sales growth supported by expansion in the U.S. and the launch of new clinical evidence such as the CeraHip study, which enhances entry into the revision arthroplasty segment. The company is actively expanding its commercial footprint using a hybrid model in additional markets like Norway and Austria, with investments expected to be cash flow neutral within two years. In 2024 and 2025, Bonesupport posted significant revenue growth, with over 40% sales growth guidance maintained for 2025, reflecting robust U.S. market performance and expanding clinical adoption. Additionally, the company has shifted the regulatory pathway for its CERAMENT V product to the De Novo process to support its market launch for treating bone infections. Bonesupport continues to invest in expanding its product portfolio and geographic reach, including potential ventures into the spine segment by the end of 2025, reinforcing its position in the orthobiologics field as a leader in advanced bone treatment solutions.

Company News

APIChatGPT

  • seekingalpha.com

    Bonesupport Holding AB (publ) (BOEUF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Bonesupport Holding AB (publ) (BOEUF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Bonesupport Holding AB (publ) (BOEUF) Q4 2025 Earnings Call Transcript